RxDoctor Payments Data

Terrance Naberhaus

Optometrist · Melbourne, FLNPI 1144200841

Payments from drug & device makers

$1,666in general payments, 2019–2025

Across 23 payments — averaging $72.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$362
  • Alcon$276
  • Oyster Point Pharma, Inc.$148
  • Amgen$125
  • Sun Pharmaceutical Industries Inc.$122
  • Aerie Pharmaceuticals, Inc.$113
  • plus $519 from 7 others

What the payments were for

  • Food & beverage$1,666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,666 in reported general payments places this provider in the 65th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$114,701
Medicare patients
610
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost82$42,158
RestasisCyclosporine29$30,135
SimbrinzaBrinzolamide/Brimonidine Tart32$11,084
CombiganBrimonidine Tartrate/Timolol16$6,871
Travoprost35$6,285
Latanoprost261$4,107
RhopressaNetarsudil Mesylate11$3,967
TobradexTobramycin/Dexamethasone11$2,860
Brimonidine Tartrate62$2,822
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,688
Timolol Maleate103$1,661
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat74$1,608
Prednisolone Acetate33$1,368
Dorzolamide Hcl39$787
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$103$79,165127 claims
AlconSimbrinza$276$11,08432 claims
Aerie Pharmaceuticals, Inc.Rhopressa$113$3,96711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →